Analysts See $0.03 EPS for DexCom, Inc. (DXCM)

February 14, 2018 - By Henry Gaston

 Analysts See $0.03 EPS for DexCom, Inc. (DXCM)
Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.39, from 1.36 in 2017Q2. It dived, as 59 investors sold DexCom, Inc. shares while 69 reduced holdings. 31 funds opened positions while 93 raised stakes. 98.30 million shares or 1.76% more from 96.59 million shares in 2017Q2 were reported.
Panagora Asset Mngmt owns 2,050 shares. First Mercantile reported 4,203 shares. Nomura Asset Management Limited holds 0.01% or 10,900 shares. Voya Invest Mgmt Ltd Co reported 32,620 shares. Quantbot Limited Partnership reported 22,485 shares stake. The Oklahoma-based Bokf Na has invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Bessemer Group holds 0% or 265 shares. C World Grp Holding A S holds 0.04% in DexCom, Inc. (NASDAQ:DXCM) or 56,835 shares. Stephens Inv Mgmt Ltd Liability Company invested 0.22% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Loring Wolcott And Coolidge Fiduciary Advisors Llp Ma has invested 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Shine Advisory Services Inc reported 0.03% stake. Raymond James & Assoc reported 72,052 shares. Ameriprise Inc reported 25,058 shares. Manufacturers Life Insur The accumulated 3,503 shares. Livforsakringsbolaget Skandia Omsesidigt accumulated 1,600 shares.

Since August 23, 2017, it had 0 insider purchases, and 11 insider sales for $2.57 million activity. 6,000 DexCom, Inc. (NASDAQ:DXCM) shares with value of $353,092 were sold by SAYER KEVIN R. Shares for $114,080 were sold by DOUBLEDAY RICHARD on Monday, September 25. 3,987 shares valued at $300,045 were sold by Pacelli Steven Robert on Wednesday, August 23. 3,245 shares valued at $198,691 were sold by Balo Andrew K on Monday, December 11.

Analysts expect DexCom, Inc. (NASDAQ:DXCM) to report $0.03 EPS on February, 27.They anticipate $0.12 EPS change or 133.33 % from last quarter’s $-0.09 EPS. DXCM’s profit would be $2.61M giving it 455.58 P/E if the $0.03 EPS is correct. After having $-0.03 EPS previously, DexCom, Inc.’s analysts see -200.00 % EPS growth. The stock decreased 0.04% or $0.02 during the last trading session, reaching $54.67. About 572,861 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 9.41% since February 14, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 23 analysts covering Dexcom (NASDAQ:DXCM), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Dexcom had 63 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 2. The firm earned “Buy” rating on Thursday, July 13 by Cowen & Co. The stock has “Neutral” rating by JP Morgan on Thursday, September 28. On Wednesday, February 24 the stock rating was maintained by JP Morgan with “Overweight”. On Tuesday, January 3 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. On Monday, November 2 the stock rating was initiated by Morgan Stanley with “Overweight”. BMO Capital Markets maintained DexCom, Inc. (NASDAQ:DXCM) rating on Friday, September 8. BMO Capital Markets has “Buy” rating and $90.0 target. The rating was downgraded by BTIG Research on Wednesday, September 14 to “Neutral”. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Jefferies on Thursday, July 13. Jefferies maintained DexCom, Inc. (NASDAQ:DXCM) on Wednesday, September 27 with “Buy” rating.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $4.75 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

More recent DexCom, Inc. (NASDAQ:DXCM) news were published by: which released: “Tandem Diabetes Care Announces Closing of $69 Million Underwritten Public …” on February 13, 2018. Also published the news titled: “Form SC 13G/A DEXCOM INC Filed by: BAILLIE GIFFORD & CO” on January 31, 2018.‘s news article titled: “DexCom Announces Upcoming Conference Presentations” with publication date: February 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.